tiprankstipranks
Vertex Pharmaceuticals (DE:VX1)
XETRA:VX1
Germany Market
VX1
Vertex Pharmaceuticals
RESEARCH TOOLSreports

Vertex Pharmaceuticals (VX1) Stock Forecast & Price Target

22 Followers
See the Price Targets and Ratings of:

VX1 Analyst Ratings

Strong Buy
22Ratings
Strong Buy
18 Buy
4 Hold
0 Sell
Based on 22 analysts giving stock ratings to
Vertex
Pharmaceuticals
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

VX1 Stock 12 Month Forecast

Average Price Target

€486.26
▲(30.96% Upside)
Based on 22 Wall Street analysts offering 12 month price targets for Vertex Pharmaceuticals in the last 3 months. The average price target is €486.26 with a high forecast of €554.82 and a low forecast of €377.38. The average price target represents a 30.96% change from the last price of €371.30.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"329":"€329","442":"€442","555":"€555","385.5":"€385.5","498.5":"€498.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":554.82415871,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€554.82</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":486.2626709968421,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€486.26</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":377.38429516,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€377.38</span>\n  </div></div>","useHTML":true}}],"tickPositions":[329,385.5,442,498.5,555],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Sep<br/>2025","6":"Dec<br/>2025","9":"Mar<br/>2026","12":"Jun<br/>2026","25":"Jun<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,373.2,387.17108913153845,401.1421782630769,415.1132673946154,429.08435652615384,443.0554456576923,457.02653478923077,470.99762392076923,484.9687130523077,498.93980218384615,512.9108913153846,526.8819804469231,540.8530695784616,{"y":554.82415871,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,373.2,381.8971285382186,390.59425707643726,399.29138561465584,407.9885141528745,416.6856426910931,425.38277122931174,434.0798997675304,442.77702830574896,451.4741568439676,460.1712853821862,468.8684139204048,477.56554245862344,{"y":486.2626709968421,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,373.2,373.5218688584615,373.84373771692304,374.16560657538463,374.48747543384616,374.8093442923077,375.1312131507692,375.4530820092308,375.7749508676923,376.09681972615385,376.4186885846154,376.74055744307697,377.0624263015385,{"y":377.38429516,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":387.45,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 36,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 36, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":384.7,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 37,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 35, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":396.85,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 35,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 28, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":330.45,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":346.55,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 37,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":366.55,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 37,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":368.7,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 41,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":391.35,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 47,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":398,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 50,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":415,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 56,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":389.3,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 45,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":366,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 42,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":373.2,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target€554.82Average Price Target€486.26Lowest Price Target€377.38
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Wells Fargo Analyst forecast on DE:VX1
Mohit Bansal
Wells Fargo
Wells Fargo
€476.06
Buy
28.21%
Upside
Reiterated
06/11/26
Vertex Pharmaceuticals (VRTX) Receives a Buy from Wells Fargo
Goldman Sachs Analyst forecast on DE:VX1
Salveen Richter
Goldman Sachs
Goldman Sachs
€554.82
Buy
49.43%
Upside
Reiterated
06/10/26
Analysts Are Bullish on Top Healthcare Stocks: Harmony Biosciences Holdings (HRMY), Vertex Pharmaceuticals (VRTX)
RBC Capital Analyst forecast on DE:VX1
Brian Abrahams
RBC Capital
RBC Capital
€470
Buy
26.58%
Upside
Reiterated
06/04/26
Analysts' Opinions Are Mixed on These Healthcare Stocks: Viatris (NASDAQ: VTRS), Medtronic (NYSE: MDT) and Vertex Pharmaceuticals (NASDAQ: VRTX)
Guggenheim Analyst forecast on DE:VX1
Unknown Analyst
Guggenheim
Not Ranked
Guggenheim
€472.6
Buy
27.28%
Upside
Reiterated
06/02/26
Guggenheim Sticks to Their Buy Rating for Vertex Pharmaceuticals (VRTX)
Maxim Group Analyst forecast on DE:VX1
Naz Rahman
Maxim Group
Maxim Group
€497.7
Buy
34.04%
Upside
Reiterated
06/02/26
Analysts' Top Healthcare Picks: Vertex Pharmaceuticals (VRTX), Bicara Therapeutics Inc. (BCAX)
Truist Financial Analyst forecast on DE:VX1
Danielle Brill
Truist Financial
Truist Financial
€454.42→€469.13
Buy
26.35%
Upside
Initiated
05/27/26
Vertex Pharmaceuticals assumed with a Buy at TruistVertex Pharmaceuticals assumed with a Buy at Truist
J.P. Morgan Analyst forecast on DE:VX1
Unknown Analyst
J.P. Morgan
Not Ranked
J.P. Morgan
€445.76
Buy
20.05%
Upside
Reiterated
05/20/26
J.P. Morgan Reaffirms Their Buy Rating on Vertex Pharmaceuticals (VRTX)
Barclays Analyst forecast on DE:VX1
Eliana Merle
Barclays
Barclays
€525.4→€532.32
Buy
43.37%
Upside
Reiterated
05/06/26
Barclays Reaffirms Their Buy Rating on Vertex Pharmaceuticals (VRTX)
William Blair Analyst forecast on DE:VX1
Myles Minter
William Blair
William Blair
―
Buy
―
Reiterated
05/05/26
Analysts Are Bullish on Top Healthcare Stocks: Addus Homecare (ADUS), Vertex Pharmaceuticals (VRTX)
Needham Analyst forecast on DE:VX1
Joseph Stringer
Needham
Needham
―
Hold
―
Reiterated
05/05/26
Analyst Maintains Hold on Vertex as Strong CF Franchise Offsets Mixed Q1 Results and Non‑CF Pipeline Uncertainty
Oppenheimer Analyst forecast on DE:VX1
Jay Olson
Oppenheimer
Oppenheimer
€519.34
Buy
39.87%
Upside
Reiterated
05/05/26
Analysts Are Bullish on These Healthcare Stocks: Vertex Pharmaceuticals (VRTX), Eli Lilly & Co (LLY)
Evercore ISI Analyst forecast on DE:VX1
Cory Kasimov
Evercore ISI
Evercore ISI
€458.75→€463.07
Buy
24.72%
Upside
Reiterated
05/05/26
Vertex Pharmaceuticals (VRTX) Gets a Buy from Evercore ISI
Stifel Nicolaus Analyst forecast on DE:VX1
Paul Matteis
Stifel Nicolaus
Stifel Nicolaus
€403.35
Hold
8.63%
Upside
Reiterated
05/05/26
Stifel Nicolaus Remains a Hold on Vertex Pharmaceuticals (VRTX)
Canaccord Genuity Analyst forecast on DE:VX1
Whitney Ijem
Canaccord Genuity
Canaccord Genuity
€378.25→€377.38
Hold
1.64%
Upside
Reiterated
05/05/26
Vertex Pharmaceuticals price target lowered to $436 from $437 at CanaccordVertex Pharmaceuticals price target lowered to $436 from $437 at Canaccord
Morgan Stanley Analyst forecast on DE:VX1
Terence Flynn
Morgan Stanley
Morgan Stanley
€529.72→€533.19
Buy
43.60%
Upside
Assigned
05/05/26
Morgan Stanley Remains a Buy on Vertex Pharmaceuticals (VRTX)
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Wells Fargo Analyst forecast on DE:VX1
Mohit Bansal
Wells Fargo
Wells Fargo
€476.06
Buy
28.21%
Upside
Reiterated
06/11/26
Vertex Pharmaceuticals (VRTX) Receives a Buy from Wells Fargo
Goldman Sachs Analyst forecast on DE:VX1
Salveen Richter
Goldman Sachs
Goldman Sachs
€554.82
Buy
49.43%
Upside
Reiterated
06/10/26
Analysts Are Bullish on Top Healthcare Stocks: Harmony Biosciences Holdings (HRMY), Vertex Pharmaceuticals (VRTX)
RBC Capital Analyst forecast on DE:VX1
Brian Abrahams
RBC Capital
RBC Capital
€470
Buy
26.58%
Upside
Reiterated
06/04/26
Analysts' Opinions Are Mixed on These Healthcare Stocks: Viatris (NASDAQ: VTRS), Medtronic (NYSE: MDT) and Vertex Pharmaceuticals (NASDAQ: VRTX)
Guggenheim Analyst forecast on DE:VX1
Unknown Analyst
Guggenheim
Not Ranked
Guggenheim
€472.6
Buy
27.28%
Upside
Reiterated
06/02/26
Guggenheim Sticks to Their Buy Rating for Vertex Pharmaceuticals (VRTX)
Maxim Group Analyst forecast on DE:VX1
Naz Rahman
Maxim Group
Maxim Group
€497.7
Buy
34.04%
Upside
Reiterated
06/02/26
Analysts' Top Healthcare Picks: Vertex Pharmaceuticals (VRTX), Bicara Therapeutics Inc. (BCAX)
Truist Financial Analyst forecast on DE:VX1
Danielle Brill
Truist Financial
Truist Financial
€454.42→€469.13
Buy
26.35%
Upside
Initiated
05/27/26
Vertex Pharmaceuticals assumed with a Buy at TruistVertex Pharmaceuticals assumed with a Buy at Truist
J.P. Morgan Analyst forecast on DE:VX1
Unknown Analyst
J.P. Morgan
Not Ranked
J.P. Morgan
€445.76
Buy
20.05%
Upside
Reiterated
05/20/26
J.P. Morgan Reaffirms Their Buy Rating on Vertex Pharmaceuticals (VRTX)
Barclays Analyst forecast on DE:VX1
Eliana Merle
Barclays
Barclays
€525.4→€532.32
Buy
43.37%
Upside
Reiterated
05/06/26
Barclays Reaffirms Their Buy Rating on Vertex Pharmaceuticals (VRTX)
William Blair Analyst forecast on DE:VX1
Myles Minter
William Blair
William Blair
―
Buy
―
Reiterated
05/05/26
Analysts Are Bullish on Top Healthcare Stocks: Addus Homecare (ADUS), Vertex Pharmaceuticals (VRTX)
Needham Analyst forecast on DE:VX1
Joseph Stringer
Needham
Needham
―
Hold
―
Reiterated
05/05/26
Analyst Maintains Hold on Vertex as Strong CF Franchise Offsets Mixed Q1 Results and Non‑CF Pipeline Uncertainty
Oppenheimer Analyst forecast on DE:VX1
Jay Olson
Oppenheimer
Oppenheimer
€519.34
Buy
39.87%
Upside
Reiterated
05/05/26
Analysts Are Bullish on These Healthcare Stocks: Vertex Pharmaceuticals (VRTX), Eli Lilly & Co (LLY)
Evercore ISI Analyst forecast on DE:VX1
Cory Kasimov
Evercore ISI
Evercore ISI
€458.75→€463.07
Buy
24.72%
Upside
Reiterated
05/05/26
Vertex Pharmaceuticals (VRTX) Gets a Buy from Evercore ISI
Stifel Nicolaus Analyst forecast on DE:VX1
Paul Matteis
Stifel Nicolaus
Stifel Nicolaus
€403.35
Hold
8.63%
Upside
Reiterated
05/05/26
Stifel Nicolaus Remains a Hold on Vertex Pharmaceuticals (VRTX)
Canaccord Genuity Analyst forecast on DE:VX1
Whitney Ijem
Canaccord Genuity
Canaccord Genuity
€378.25→€377.38
Hold
1.64%
Upside
Reiterated
05/05/26
Vertex Pharmaceuticals price target lowered to $436 from $437 at CanaccordVertex Pharmaceuticals price target lowered to $436 from $437 at Canaccord
Morgan Stanley Analyst forecast on DE:VX1
Terence Flynn
Morgan Stanley
Morgan Stanley
€529.72→€533.19
Buy
43.60%
Upside
Assigned
05/05/26
Morgan Stanley Remains a Buy on Vertex Pharmaceuticals (VRTX)
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
TRAXFirst Tracks Biotherapeutics Inc
EVMNEvommune, Inc.
MPLTMapLight Therapeutics, Inc.
MAZEMaze Therapeutics, Inc.
AAPGAscentage Pharma Group International Unsponsored ADR
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Vertex Pharmaceuticals

3 Months
Mohit BansalWells Fargo
Success Rate
22/32 ratings generated profit
69%
Average Return
+6.57%
Copying Mohit Bansal's trades and holding each position for 3 Months would result in 68.75% of your transactions generating a profit, with an average return of +6.57% per trade.
1 Year
Cory KasimovEvercore ISI
Success Rate
23/33 ratings generated profit
70%
Average Return
+11.97%
Copying Cory Kasimov's trades and holding each position for 1 Year would result in 69.70% of your transactions generating a profit, with an average return of +11.97% per trade.
2 Years
Michael YeeUBS
Success Rate
24/30 ratings generated profit
80%
Average Return
+22.17%
Copying Michael Yee's trades and holding each position for 2 Years would result in 80.00% of your transactions generating a profit, with an average return of +22.17% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

VX1 Analyst Recommendation Trends

Rating
Feb 26
Mar 26
Apr 26
May 26
Jun 26
Strong Buy
0
0
0
0
0
Buy
50
56
45
42
30
Hold
7
11
13
11
7
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
57
67
58
53
37
In the current month, VX1 has received 30 Buy Ratings, 7 Hold Ratings, and 0 Sell Ratings. VX1 average Analyst price target in the past 3 months is 486.26.
Each month's total comprises the sum of three months' worth of ratings.

VX1 Financial Forecast

VX1 Earnings Forecast

Next quarter’s earnings estimate for VX1 is €4.09 with a range of €3.45 to €4.47. The previous quarter’s EPS was €3.87. VX1 beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year VX1 has Performed in-line its overall industry.
Next quarter’s earnings estimate for VX1 is €4.09 with a range of €3.45 to €4.47. The previous quarter’s EPS was €3.87. VX1 beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year VX1 has Performed in-line its overall industry.

VX1 Sales Forecast

Next quarter’s sales forecast for VX1 is €2.78B with a range of €2.69B to €2.87B. The previous quarter’s sales results were €2.61B. VX1 beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year VX1 has Performed in-line its overall industry.
Next quarter’s sales forecast for VX1 is €2.78B with a range of €2.69B to €2.87B. The previous quarter’s sales results were €2.61B. VX1 beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year VX1 has Performed in-line its overall industry.

VX1 Stock Forecast FAQ

What is DE:VX1’s average 12-month price target, according to analysts?
Based on analyst ratings, Vertex Pharmaceuticals’s 12-month average price target is 486.26.
    What is DE:VX1’s upside potential, based on the analysts’ average price target?
    Vertex Pharmaceuticals has 30.96% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is Vertex Pharmaceuticals a Buy, Sell or Hold?
          Vertex Pharmaceuticals has a consensus rating of Strong Buy, which is based on 18 buy ratings, 4 hold ratings and 0 sell ratings.
            What is Vertex Pharmaceuticals’s share price target?
            The average share price target for Vertex Pharmaceuticals is 486.26. This is based on 22 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst share price target is €554.82 ,and the lowest forecast is €377.38. The average share price target represents 30.96% Increase from the current price of €371.3.
              What do analysts say about Vertex Pharmaceuticals?
              Vertex Pharmaceuticals’s analyst rating consensus is a Strong Buy. This is based on the ratings of 22 Wall Streets Analysts.
                How can I buy shares of Vertex Pharmaceuticals?
                To buy shares of DE:VX1, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.